MannKind Corp. (MNKD) Approved for Inhaled Insulin Treatment
June 30, 2014 at 09:25 AM EDT
Shares of MannKind Corporation (MNKD) were trading up +1.90 or +19.00 percent to $11.90 per share in pre-market trading Monday morning. ManKind announced over the weekend that the company had finally gained approval for its inhaled insulin drug AFREZZA from the U.S. Food and Drug Administration or FDA. MannKind shares closed at $10.00 per share, Read the full article... Read the rest of MannKind Corp. (MNKD) Approved for Inhaled Insulin Treatment at InvestorGuide.com .
